A carregar...
CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies
As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter these agents. While blockade of immune checkpoint target proteins (CTLA-4, PD-1, PD-L1) generates an antitumor response in a sub...
Na minha lista:
| Publicado no: | J Am Acad Dermatol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7572574/ https://ncbi.nlm.nih.gov/pubmed/32461079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaad.2020.03.131 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|